Get the Stockscreener App
11.45
5.72%
0.62
Polyrizon Ltd stock is traded at $11.45, with a volume of 81,639.
It is up +5.72% in the last 24 hours and down -22.64% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$10.83
Open:
$10.82
24h Volume:
81,639
Relative Volume:
1.93
Market Cap:
$23.86M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-4.2415
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
+0.00%
1M Performance:
-22.64%
6M Performance:
+2.32%
1Y Performance:
+137.89%
1-Day Range:
$10.52
$12.28
1-Week Range:
$10.45
$12.60
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
11.45 | 22.57M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Canada
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com India
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - The Manila Times
Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology - Quiver Quantitative
Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates - The Globe and Mail
Polyrizon schedules annual shareholder meeting for July 13 By Investing.com - Investing.com Canada
Polyrizon Secures Three Key U.S. Sites for NASARIX Allergy Trial - TipRanks
Polyrizon schedules annual shareholder meeting for July 13 - Investing.com
Polyrizon (PLRZ) 2026 AGM to vote on compensation policy, major RSU grants and Deloitte re-appointment - Stock Titan
Polyrizon (Nasdaq: PLRZ) signs 3 key U.S. sites for NASARIX allergy trial - Stock Titan
Polyrizon signs two more U.S. sites for allergy trial By Investing.com - Investing.com South Africa
Polyrizon signs two more U.S. sites for allergy trial - Investing.com
Polyrizon Ltd. Expands Clinical Trial Network for NASARIX™ Allergy Blocker with Two New U.S. Sites - Quiver Quantitative
New nasal gel trial to block airborne seasonal allergens in U.S. - Stock Titan
Polyrizon extends exclusivity for 51% Arrow Aviation acquisition - scanx.trade
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks By Investing.com - Investing.com Nigeria
Polyrizon Extends Exclusivity on Proposed 51% Acquisition of Arrow Aviation - TipRanks
Polyrizon extends exclusivity period for Arrow Aviation acquisition talks - Investing.com
Polyrizon (NASDAQ: PLRZ) prolongs Arrow Aviation 51% stake talks - Stock Titan
Polyrizon Shares Flat After Delay in New Filing Near Highs - Bez Kabli
Polyrizon Appoints Veteran Entrepreneur Ami Oren to Board of Directors - The Globe and Mail
Polyrizon Ltd. (PLRZ) Posts Modest Gain as Stock Consolidates Near Support LevelsETH Profile - The Legal Advocate
Polyrizon (PLRZ) appoints entrepreneur Ami Oren as new Class I director - Stock Titan
Polyrizon Ltd. (PLRZ) Soars Over 20%: Key Levels and Potential ScenariosBollinger Squeeze - The Legal Advocate
Polyrizon Ltd. (PLRZ) Surges Over 20% — Key Resistance Level in FocusOpen Trading Community - Newser
PLRZ Technical Analysis | Trend, Signals & Chart Patterns | POLYRIZON LTD (NASDAQ:PLRZ) - ChartMill
Number of shareholders of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TipRanks
Polyrizon signs first clinical trial agreement for allergy drug By Investing.com - Investing.com India
Polyrizon Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Trial - geneonline.com
Polyrizon signs first clinical trial agreement for allergy drug - Investing.com
Polyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker Trial - TipRanks
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan
Nasal spray to block airborne allergens heads to first U.S. allergy trial site - Stock Titan
TradingKey - TradingKey
Polyrizon develops nasal barrier tech to block multiple respiratory viruses amid rising viral threats - Pluang
Nasal barrier tech: how Polyrizon wants to plug gaps before vaccines - Stock Titan
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polyrizon Ltd Stock (PLRZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):